Breaking News

Asieris & CDC Sign Investigational Drug Supply Agreement for APL-1202

The agreement enables new treatment options for FLA patients in the U.S.

Author Image

By: Charlie Sternberg

Associate Editor

Asieris Pharmaceuticals, a global biopharmaceutical company, has signed an investigational drug supply agreement under the Expanded Access Investigational New Drug (IND) Program with the Centers for Disease Control and Prevention (CDC) in the U.S. for the independently developed APL-1202 (nitroxoline), subject to evaluation by CDC experts, to be used for treating Free-living Amoebae (FLA) infections. Infections by free-living amebae (FLA) like Acanthamoeba, Balamuthia mandrillaris, and Naegle...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters